CN103421092A - 一种阿托西班的纯化方法 - Google Patents
一种阿托西班的纯化方法 Download PDFInfo
- Publication number
- CN103421092A CN103421092A CN2013104013947A CN201310401394A CN103421092A CN 103421092 A CN103421092 A CN 103421092A CN 2013104013947 A CN2013104013947 A CN 2013104013947A CN 201310401394 A CN201310401394 A CN 201310401394A CN 103421092 A CN103421092 A CN 103421092A
- Authority
- CN
- China
- Prior art keywords
- atosiban
- acetonitrile
- gradient
- regulated
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002403 atosiban Drugs 0.000 title claims abstract description 124
- 108700007535 atosiban Proteins 0.000 title claims abstract description 94
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000000746 purification Methods 0.000 title abstract description 17
- 239000012043 crude product Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 66
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 64
- 239000012535 impurity Substances 0.000 claims description 41
- 229960000583 acetic acid Drugs 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 235000019257 ammonium acetate Nutrition 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 14
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 13
- 239000005695 Ammonium acetate Substances 0.000 claims description 13
- 229940043376 ammonium acetate Drugs 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000005277 cation exchange chromatography Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 abstract description 14
- 239000012071 phase Substances 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 239000013558 reference substance Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 229920005989 resin Polymers 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000019837 monoammonium phosphate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- XUKUVROJKPSLLU-XMMPIXPASA-N (2r)-3-(4-ethoxyphenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 XUKUVROJKPSLLU-XMMPIXPASA-N 0.000 description 1
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- AECGEIVNZGQBJT-UHFFFAOYSA-N 3-tritylsulfanylpropanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCCC(=O)O)C1=CC=CC=C1 AECGEIVNZGQBJT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000035010 Term birth Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229940030215 pitocin Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
时间,天 | 外观、性状 | 有关物质 |
0 | 为白色粉末 | 未见杂质斑点 |
10 | 为白色粉末 | 未见杂质斑点 |
30 | 为白色粉末 | 未见杂质斑点 |
60 | 为白色粉末 | 未见杂质斑点 |
90 | 为白色粉末 | 未见杂质斑点 |
时间,天 | 外观、性状 | 有关物质 |
0 | 为白色粉末 | 未见杂质斑点 |
10 | 为白色粉末 | 未见杂质斑点 |
30 | 为白色粉末 | 未见杂质斑点 |
60 | 为白色粉末 | 未见杂质斑点 |
90 | 为浅黄色粉末 | 可见杂质斑点 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310401394.7A CN103421092B (zh) | 2013-09-05 | 2013-09-05 | 一种阿托西班的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310401394.7A CN103421092B (zh) | 2013-09-05 | 2013-09-05 | 一种阿托西班的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103421092A true CN103421092A (zh) | 2013-12-04 |
CN103421092B CN103421092B (zh) | 2015-05-13 |
Family
ID=49646508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310401394.7A Expired - Fee Related CN103421092B (zh) | 2013-09-05 | 2013-09-05 | 一种阿托西班的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103421092B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105949283A (zh) * | 2016-06-07 | 2016-09-21 | 海南合瑞制药股份有限公司 | 醋酸阿托西班杂质、制备及检测方法 |
CN106279367A (zh) * | 2016-08-15 | 2017-01-04 | 海南合瑞制药股份有限公司 | 一种醋酸阿托西班晶体及其制备方法 |
WO2020114002A1 (zh) * | 2018-12-04 | 2020-06-11 | 深圳翰宇药业股份有限公司 | 一种glp-1类似多肽的纯化方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101696959A (zh) * | 2009-02-11 | 2010-04-21 | 海南中和药业有限公司 | 一种醋酸阿托西班及其制剂的含量测定和有关物质测定的方法 |
CN101981048A (zh) * | 2008-02-06 | 2011-02-23 | 拜康有限公司 | 纯化肽的方法 |
CN102584953A (zh) * | 2012-02-09 | 2012-07-18 | 深圳翰宇药业股份有限公司 | 一种阿托西班的纯化方法 |
-
2013
- 2013-09-05 CN CN201310401394.7A patent/CN103421092B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101981048A (zh) * | 2008-02-06 | 2011-02-23 | 拜康有限公司 | 纯化肽的方法 |
CN101696959A (zh) * | 2009-02-11 | 2010-04-21 | 海南中和药业有限公司 | 一种醋酸阿托西班及其制剂的含量测定和有关物质测定的方法 |
CN102584953A (zh) * | 2012-02-09 | 2012-07-18 | 深圳翰宇药业股份有限公司 | 一种阿托西班的纯化方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105949283A (zh) * | 2016-06-07 | 2016-09-21 | 海南合瑞制药股份有限公司 | 醋酸阿托西班杂质、制备及检测方法 |
CN106279367A (zh) * | 2016-08-15 | 2017-01-04 | 海南合瑞制药股份有限公司 | 一种醋酸阿托西班晶体及其制备方法 |
CN106279367B (zh) * | 2016-08-15 | 2019-06-04 | 海南合瑞制药股份有限公司 | 一种醋酸阿托西班晶体及其制备方法 |
WO2020114002A1 (zh) * | 2018-12-04 | 2020-06-11 | 深圳翰宇药业股份有限公司 | 一种glp-1类似多肽的纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103421092B (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103435687B (zh) | 一种卡贝缩宫素的纯化方法 | |
CN102875655B (zh) | 一种合成利那洛肽的方法 | |
CN111647048B (zh) | 干扰多肽在制备抗SARS-CoV-2药物中的应用 | |
CN103012564B (zh) | 高纯度的曲普瑞林及其纯化方法 | |
CN102408471A (zh) | 特利加压素的制备方法 | |
CN105131084B (zh) | 基于内吗啡肽2或Biphalin的棕榈酰化修饰的阿片肽类似物及其合成和应用 | |
CN102464702A (zh) | 制备醋酸亮丙瑞林的方法、产品及用途 | |
CN104177490B (zh) | 片段缩合制备醋酸鲑鱼降钙素的方法 | |
CN103421092B (zh) | 一种阿托西班的纯化方法 | |
CN104861042A (zh) | 特异性微波合成制备醋酸西曲瑞克的方法 | |
CN103992391A (zh) | 一种纯化特利加压素的方法 | |
CN108659099B (zh) | 一种用于血管紧张素转化酶活性检测的质谱探针及其应用 | |
CN104086632A (zh) | 一种制备西曲瑞克的方法 | |
CN104861045A (zh) | 环肽化合物gg6f及其制备方法 | |
CN103467574B (zh) | 一种醋酸去氨加压素的纯化方法 | |
CN103665115B (zh) | 环十肽化合物gg-110824的化学制备方法 | |
CN107056894A (zh) | 一种片段法固相合成醋酸加尼瑞克的方法 | |
CN105001307A (zh) | 一种溶解难溶多肽的偶联肽链及其在液相色谱中分离纯化的应用 | |
CN103980357A (zh) | 一种合成胸腺法新的方法 | |
CN104163853A (zh) | 一种制备利那洛肽的方法 | |
CN104211801A (zh) | 一种制备利西拉来的方法 | |
CN106084015B (zh) | 一种合成卡贝缩宫素的方法 | |
CN103012596B (zh) | 具有血脑屏障通透性的内吗啡肽衍生肽及其合成和应用 | |
CN112062829A (zh) | 依降钙素的制备方法 | |
CN103467593B (zh) | 一种胸腺法新的纯化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 310018 Zhejiang Province, Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Applicant after: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: Hangzhou City, Zhejiang province Xiasha 310018 No. six Street No. 452 high-tech business incubator Park Building 1 3B01 Hangzhou sinopep Pharmaceutical Technology Co Ltd Applicant before: Hangzhou Sinopep Pharmaceutical Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HANGZHOU SINOPEP PHARMACEUTICAL INC. TO: HANGZHOU ADELAI NUOTAI PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Atosiban purification method Effective date of registration: 20150807 Granted publication date: 20150513 Pledgee: Hangzhou United Rural Commercial Bank Limited by Share Ltd. branch of science and technology Pledgor: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: 2015330000033 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 310018 Zhejiang Province, Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee after: ADLAI NORTYE BIOPHARMA Co.,Ltd. Address before: 310018 Zhejiang Province, Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee before: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190114 Granted publication date: 20150513 Pledgee: Hangzhou United Rural Commercial Bank Limited by Share Ltd. branch of science and technology Pledgor: Hangzhou Arnold Biomedical Technology Co.,Ltd. Registration number: 2015330000033 |
|
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20190114 Registration number: 2015330000033 Pledgor after: Hangzhou Arnold Biomedical Technology Co.,Ltd. Pledgor before: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
PM01 | Change of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: 310018 Building C2109-2117, D2101-2117, 452 No. 6 Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province Patentee after: Hangzhou Arnold Biomedical Technology Co.,Ltd. Address before: 310018 Hangzhou Economic and Technological Development Zone, Zhejiang Province, No. 452, No. 6 Street, No. 1 Hangzhou High-tech Incubator Building 3B01-3B04 Patentee before: ADLAI NORTYE BIOPHARMA Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Atosiban purification method Effective date of registration: 20190215 Granted publication date: 20150513 Pledgee: Hangzhou United Rural Commercial Bank Limited by Share Ltd. branch of science and technology Pledgor: Hangzhou Arnold Biomedical Technology Co.,Ltd. Registration number: 2019330000054 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201010 Granted publication date: 20150513 Pledgee: Hangzhou United Rural Commercial Bank Limited by Share Ltd. branch of science and technology Pledgor: Hangzhou Arnold Biomedical Technology Co.,Ltd. Registration number: 2019330000054 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150513 Termination date: 20210905 |
|
CF01 | Termination of patent right due to non-payment of annual fee |